Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 6/20 | 0.44 |
| ▸ | PGR | P06401 | 4/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004996 | 0.86 | CYP46A1 (0.40) | CYP46A1PGRNR3C1HTR2ANR1I2 | |
| SCHEMBL7656943 | 0.82 | PGR (0.39) | CYP46A1PGRNR3C1HTR2ANR1I2 | |
| SCHEMBL7006781 | 0.76 | CYP46A1 (0.52) | CYP46A1PGRNR3C1HTR2ANR1I2 | |
| SCHEMBL7237856 | 0.74 | ADRA2C (0.33) | HTR2AADRA2CTACR2ADRA1DPTH1R | |
| SCHEMBL6986440 | 0.71 | HTR2A (0.45) | CYP46A1PGRNR3C1HTR2ANR1I2 | |
| SCHEMBL7636124 | 0.69 | ADRA2C (0.32) | PGRHTR2AADRA2CTACR2ADRA1D | |
| SCHEMBL20656331 | 0.68 | ELOVL6 (0.41) | CYP46A1PGRNR3C1HTR2AELOVL6 | |
| SCHEMBL7185285 | 0.67 | CYP46A1 (0.70) | CYP46A1PGRNR3C1HTR2ANR1I2 | |
| SCHEMBL1152420 | 0.65 | PGR (0.49) | CYP46A1PGRNR3C1HTR2ANR1I2 | |
| SCHEMBL1152913 | 0.65 | PGR (0.49) | CYP46A1PGRNR3C1HTR2ANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359147-A1 | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same | Bristol-Myers Squibb Pharma Company (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-0929533-B1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6492515-B2 | FOR THERAPY OF HIV INFECTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6489320-B1 | NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND BENZOXAPINONE FOR TREATMENT OF HIV INFECTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20020040138-A1 | 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-04 | — | — | US | disclosed |
| US-6303780-B1 | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
| US-6140499-A | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICAL COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6140320-A | FOR TREATING HIV(HUMAN IMMUNODEFICIENCY VIRUS) INFECTIONS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-5874430-A | COMPOUNDS AS PROTEASE, REVERSE TRANSCRIPTASE INHIBITORS FOR DIAGNOSIS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040138-A1 | 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DHX15, CYP4X1, DPYD | CYP46A1 486/4885PGR 1770/4885NR3C1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.